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Abstract
Background: Glucagon-like peptide-1 is an incretin hormone essential for normal human glucose homeostasis.
Expression of the glucagon-like peptide-1 receptor in the myocardium has fuelled growing interest in the direct
and indirect cardiovascular effects of native glucagon-like peptide-1, its degradation product glucagon-like
peptide-1(9-36), and the synthetic glucagon-like peptide-1 receptor agonists. Preclinical studies have demonstrated
cardioprotective actions of all three compounds in the setting of experimental myocardial infarction and left
ventricular systolic dysfunction. This has led to Phase 2 trials of native glucagon-like peptide-1 and incretin-based
therapies in humans with and without Type 2 diabetes mellitus. These studies have demonstrated the ability of
glucagon-like peptide-1, independent of glycaemic control, to positively modulate the metabolic and haemodynamic
parameters of individuals with coronary artery disease and left ventricular systolic dysfunction. We aim to add
to this growing body of evidence by studying the effect of chronic glucagon-like peptide-1 receptor activation on
exercise-induced ischaemia in patients with chronic stable angina managed conservatively or awaiting revascularisation.
The hypothesis being liraglutide, a subcutaneously injectable glucagon-like peptide-1 receptor agonist, is able to improve
exercise haemodynamics in patients with obstructive coronary artery disease when compared with saline placebo.
Methods and design: The Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) trial is
an investigator-initiated single-centre randomised double-blinded placebo-controlled crossover proof-of-principle
physiological study. Primary endpoints are change in rate pressure product at 0.1 mV ST-segment depression and
change in degree of ST-segment depression at peak exercise during sequential exercise tolerance testing performed
over a 6-week study period in which 26 patients will be randomised to either liraglutide or saline with crossover to the
opposing regimen at week 3.
Discussion: The study will be conducted in accordance with the principles of Good Clinical Practice and the Declaration
of Helsinki. The local Research Ethics Committee and Medicines and Healthcare Products Regulatory Agency have
approved the study.
Trial registration: National Institute of Health Research Clinical Research Network (NIHR CRN) Portfolio ID 11112 and
ClinicalTrials.gov Identifier NCT02315001.
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Background
The incretin concept was borne from the observation
that an oral load of glucose can provoke a two to
three times more potent insulinotropic stimulus than
an isoglycaemic intravenous glucose infusion [1,2].
This effect has been attributed to the action of incretin
(INtestinal seCRETion of INsulin) hormones, which
constitute part of the glucagon superfamily. Glucose-
dependent insulinotropic polypeptide (GIP), a 42-amino
acid peptide made by duodenal and jejunal enteroendocrine
K cells in the proximal small bowel, was the first incretin
hormone to be isolated from purified porcine intestinal
extracts [3]. More than a decade later, glucagon-like
peptide-1 (GLP-1) was identified, a 30-amino acid cleavage
product of proglucagon, synthesised predominantly by the
enteroendocrine L cells of the distal ileum and colon [4,5].
Despite their site of production, plasma levels of GIP and
GLP-1 rise within minutes of enteral nutrition, indicating a
combined neural and endocrine signalling axis prompting
their secretion [6]. Together, GIP and GLP-1 are funda-
mental to maintaining normal glucose homeostasis in man.
They contribute almost equally to, and have an additive
effect on, enhancing glucose-dependent insulin exocytosis
after meal ingestion, although GLP-1-mediated effects
appear to predominate at higher glucose levels [7].
There is a defective incretin effect in Type 2 diabetes
mellitus (T2DM) [8]. Levels of GIP can increase after
enteral nutrition but the ability to potentiate postprandial
insulin secretion is significantly impaired [9,10]. In
contrast, meal-stimulated levels of GLP-1 are severely
depressed. A continuous infusion of exogenous GLP-1
can, however, result in a near normal insulin-mediated
response to an oral glucose load, suggesting preservation
of insulinotropic activity [11-14]. Furthermore the risk of
hypoglycaemia with GLP-1 is minimal, as both its stimula-
tory effect on insulin secretion and its inhibitory action on
glucagon release switch off when ambient glucose levels
are <4 mmol/L [5,14,15]. Despite these properties, the
pharmaco-therapeutic utility of native GLP-1 in T2DM is
profoundly limited by its rapid inactivation by the enzyme
dipeptidyl dipeptidase-4 (DPP-4), which cleaves 2 amino
terminal peptides from GLP-1(7-36) to form the GLP-1
(9-36) metabolite [5]. GLP-1 has a half-life of <2 minutes
which means only 10-20% of total plasma GLP-1 is
biologically active [16]. Novel treatment strategies for
T2DM, based on the incretin effect, have been developed
to overcome this endogenous cul-de-sac. Subcutaneously
injectable GLP-1 receptor (GLP-1R) agonists (DPP-4
mediated degradation-resistant peptides with improved
pharmacokinetics that act via the human GLP-1R) and
oral DPP-4 inhibitors (small molecules with clinically
useful oral bioavailability that shield the endogenous
peptide from DPP-4 metabolism and thereby enhance its
innate insulinotropic activity) are now licensed and have
become part of the standard of care for the management
of T2DM [17-19]. In essence GLP-1R agonists provide
pharmacologic levels of a GLP-1R stimulus whereas
DPP-4 inhibitors preserve physiologic levels of endogenous
GLP-1 [6].
The GLP-1R is a heptahelical G-protein coupled
receptor found widely in several extra-pancreatic tissue
beds, including lung, kidney, central, enteric and peripheral
nervous systems, lymphocytes, smooth muscle cells and
atrial cardiomyocytes [20-23]. It is this expression of the
GLP-1R in the myocardium, and the overall ubiquity of the
receptor, that has fuelled growing interest in the direct and
indirect cardiovascular (CV) effects of native GLP-1
[24,25], its degradation product GLP-1(9-36) [26,27], and
the degradation-resistant GLP-1R agonists [28-30]. Indeed
knockout mice lacking the GLP-1R were shown to have a
lower resting heart rate, elevated left ventricular (LV) end
diastolic pressure and increased LV wall thickness com-
pared to wild type controls [31]. These mice also displayed
depressed LV contractility and impaired diastolic function
after insulin administration; all suggesting a pivotal role for
the GLP-1R in maintaining normal cardiac structure and
function, in mice at least [31,32]. It is also important to
note that whilst native GLP-1 may exert a regulatory role
on CV biology through its interaction with the GLP-1R
plus its independently cardioactive metabolite GLP-1(9-36),
synthetic GLP-1R agonists are shielded from DPP-4
breakdown and therefore act predominantly via their
action on the classical GLP-1R alone [5,20]. Nevertheless,
several preclinical studies have demonstrated cardioprotec-
tive actions of all three compounds in rodent, canine and
porcine hearts in the context of ischaemia/reperfusion (I/R)
injury after experimental myocardial infarction (MI) and
LV systolic dysfunction [24,26,27,29,30,33-36]. The growing
weight of evidence from these animal models has led to
several Phase 2 trials of native GLP-1 and incretin-based
therapies in humans with and without T2DM (Table 1).
Although hypothesis-generating at best, these small, often
single-centre, studies have demonstrated the ability of
GLP-1, independent of its effect on glycaemic control, to
positively modulate the metabolic and haemodynamic
parameters of individuals with CAD and cardiomyopathy
(Table 1) [37-45].
Our aim is to add to this growing body of evidence by
characterising, for the first time, the effect of chronic
GLP-1R activation on haemodynamics and exercise-
induced ischaemia in a cohort of patients with chronic
stable angina managed conservatively or awaiting
revascularisation. Rather than study I/R injury following
coronary occlusion, we will determine whether the acute
anti-ischaemic properties of GLP-1 translate into an
anti-anginal action on exertion. Liraglutide (trade name
Victoza manufactured by NovoNordisk, Bagsvaerd,
Denmark), a synthetic GLP-1R agonist that shares 97%
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Table 1 Evidence for GLP-1-mediated cardioprotection in humans
Author and
year published
Pathologic
substrate
Agent Control Hypothesis/Question Pertinent findings Potential Limitations
Nikolaidis et al.
2004 [37]
Myocardial ischaemia/
reperfusion injury
GLP-1 (N=10) Standard
therapy post
PPCI (N=11)
Can a 72-hour infusion of GLP-1
improve global and regional LV
function for post infarct myocardial
dysfunction following successful PPCI?
• GLP-1 therapy improved global
LVEF (p<0.01)
• Small, single-centre,
nonrandomized pilot study
• GLP-1 improved regional (p<0.001)
and global (p<0.001) WMSI
• Truncated 4-day follow-up
window does not allow for
extrapolation of results
• Improvements seen in diabetics and
non-diabetics and after anterior
and non-anterior MI
• GLP-1 reduced hospital stay
significantly (p<0.02)
Sokos et al.
2006 [38]
Dilated Cardiomyopathy GLP-1 (n=12) Maximum
standard
therapy (n=9)
Can a 5-week subcutaneous
infusion of GLP-1 improve both
LVEF and functional capacity?
• LVEF improved significantly in the
GLP-1 arm ((p<0.001) and was
unchanged in the control arm
• Small, single-centre, open-label,
nonrandomised study
• Type I diabetics excluded but
not Type II – potential source of
confounding and increased
incidence of hypoglycaemia
• 6MWT distance improved
significantly in the GLP-1 arm
(p<0.001)
• Quality of life improved significantly
with GLP-1 (p<0.001)
• No mention of exact infusion
volume – essential in a heart
failure cohort
• Functional improvements seen in
diabetics and non-diabetics
Sokos et al.
2007 [39]
CABG surgery GLP-1 (n=12) Standard
therapy (n=12)
Can peri- and postoperative GLP-1
administration improve haemodynamic
recovery after CABG surgery?
• No difference in LVEF or cardiac
index between the groups
• Small numbers despite
randomisation
• Control group required greater use
of inotropic and vasoactive infusions
• Hypothesis-generating
• More frequent arrhythmias seen in
control group
Halbirk et al.
2010 [40]
Ischaemic
cardiomyopathy
GLP-1 (n=10
crossover)
Saline (n=10
crossover)
GLP-1 can improve cardiac function
and exercise capacity in non-diabetic
patients with heart failure.
• Cardiac index and LVEF remained
unchanged
• Small, single-centre study
• BNP levels remained unchanged • Active intervention with a
48-hour GLP-1 infusion may
have been too short to mediate
any improvement in cardiovascular
indices
• Hypoglycaemic events related to
GLP-1 treatment were seen in 8
patients
• Trial protocol only completed in
75% of patients
Read et al.
2010 [41]
Myocardial ischaemia
(mediated by dobutamine
stress)
Sitagliptin (n=14
crossover)
Placebo (n=14
crossover)
Increased availability of endogenous
GLP-1 through DPP-4 inhibition will
protect the heart against postischaemic
LV dysfunction.
• Greater increase in myocardial
performance after sitagliptin at peak
stress (p=0.0001)
• Small study sample
• Myocardial stunning seen in
controls after dobutamine stress
whereas sitagliptin maintained LV
function
• Hypothesis-generating
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Table 1 Evidence for GLP-1-mediated cardioprotection in humans (Continued)
• Sitagliptin had a greater beneficial
effect on ischaemic vs. nonischaemic
LV segments
Read et al.
2011 [42]
Myocardial ischaemia/
reperfusion injury
GLP-1 (n=10) Saline (n=10) Can GLP-1 protect the heart against
ischaemic dysfunction associated
with serial 1-minute coronary balloon
occlusions during PCI and mitigate
myocardial stunning?
• GLP-1 infusion improved recovery
of LV systolic and diastolic function
at 30 minutes post 1-minute coronary
balloon occlusion compared with
control (p=0.02)
• Study too small to assess any
clinical endpoints
• Coronary flow not assessed
• GLP-1 infusion reduced LV
dysfunction after a second 1-minute
coronary balloon occlusion compared
with control (p=0.01)
• Hypothesis-generating
Read et al.
2012 [43]
Myocardial ischaemia
(mediated by dobutamine
stress)
GLP-1 (n=14
crossover)
Saline (n=14
crossover)
Can GLP-1 protect the heart from
ischaemic LV dysfunction and improve
myocardial response to dobutamine stress?
• Greater increase in LVEF at peak
stress during GLP-1 infusion
• Small study sample
• No myocardial stunning seen during
GLP-1 infusion
• Study not powered to examine
clinical end points
• GLP-1 improved myocardial
performance specifically in LV segments
subtended by a stenosed vessel and
did not in segments receiving an
unobstructed blood supply
Lønborg et al.
2012 [44]
Myocardial I/R injury Exenatide
(n=85)
Saline (n=87) Can exenatide protect against reperfusion
injury in STEMI patients following PPCI?
• Significantly greater myocardial
salvage index in the exenatide group
(p=0.003) post PPCI
• LVEF after 90 days was not
significantly different between
the two groups
• Patients in the exenatide group
developed significantly smaller
infarcts for an equivalent area at
risk (p=0.011)
• Study cohort too small to
detect a difference in 30-day
clinical events
McCormick et al.
2014 [45]
Myocardial ischaemia
(mediated by dobutamine
stress)
Sitagliptin
(taken for 4
weeks) (n=19)
Standard oral
hypoglycaemic
agents (n=19)
Can chronic DPP-4 inhibition with
sitagliptin protect the heart from
ischaemic LV dysfunction and
improve myocardial response to
demand ischaemia during
dobutamine stress in Type 2
diabetes patients with CAD
• No difference in the rate pressure
products at baseline, peak stress, or
recovery between the sitagliptin and
control scans
• Small study sample
• Cannot exclude degree of
variation in individual response to
dobutamine during 2 consecutive
stress echocardiograms separated
by a number of weeks
• At peak stress there was a greater
increase in global ejection fraction
following sitagliptin therapy
(p<0.0001)
• At peak stress sitagliptin enhanced
regional LV function – seen
predominantly in ischaemic segments
(p=0.001) whereas there was no effect
in non-ischaemic segments (p=0.87)
• CAD defined by the presence of
a single proximal stenosis >50% in
at least 1 epicardial coronary
artery – some might argue this
level of obstruction would not be
haemodynamically significant
Key: GLP-1 = glucagon-like peptide-1; PPCI = primary percutaneous coronary intervention; LVEF = left ventricular ejection fraction; 6MWT = 6-minute walk test; WMSI = wall motion score index; BNP = brain natriuretic
peptide; CABG = coronary artery bypass grafting; STEMI = ST-elevation myocardial infarction; PCI = percutaneous coronary intervention; DPP-4 = dipeptidyl dipeptidase-4; CAD = coronary artery disease.
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structural homology with native GLP-1, has a half-life of
10–14 hours. It binds to albumin in the circulation,
protecting it from DPP-4 degradation and preventing
renal elimination. For these reasons liraglutide is a useful
surrogate for studying chronic GLP-1R activation in
humans. Moreover the need for a continuous GLP-1
infusion is now replaced by a once daily subcutaneous
injection, which should help to maximise patient
compliance and preclude the risk of fluid overload in
those with established coronary heart disease. The
relatively small risk of hypoglycaemia associated with
liraglutide serves to further support it being used to
study the effects of GLP-1 beyond glycaemic control in
both diabetics and non-diabetics. Indeed, a trial inves-
tigating the treatment of obesity demonstrated significantly
greater weight loss achieved with liraglutide versus orlistat
or placebo and an absence of hypoglycaemic episodes
in a cohort of non-diabetics [46]. Our centre has de-
veloped reproducible exercise protocols for the study of
angina [47-50], and it is from these that the current trial
protocol has been derived.
Aims and objectives
The objective of the present protocol is to evaluate the
physiological basis of chronic GLP-1R occupancy on
exercise haemodynamics, as manifest by specific elec-
trophysiological parameters, in those patients with
known chronic stable angina, a significant coronary
stenosis in at least one major epicardial vessel confirmed
by coronary angiography and evidence of reversible
myocardial ischaemia seen on exercise tolerance testing.
The hypothesis being liraglutide, a subcutaneously inject-
able synthetic analogue of endogenous GLP-1, is able to
improve exercise haemodynamics in a cohort of patients
with obstructive coronary artery disease (CAD) when
compared with saline placebo. Primary and secondary out-
come measures are listed in Tables 2 and 3 respectively.
Methods and design
Study design
The Liraglutide to Improve corONary haemodynamics
during Exercise streSS (LIONESS) (NIHR CRN Study
ID 11112 and clinicaltrials.gov NCT02315001) trial is an
investigator-initiated single-centre randomised double-
blinded placebo-controlled crossover proof-of-principle
physiological study. Patients will be enrolled according
to the inclusion and exclusion criteria listed in Tables 4
and 5 respectively.
Both investigator and patient will be blinded to the
study drug. Patients will be randomised to enter a GLP-1
treatment arm or matched-volume saline placebo arm.
Following a 1-week run-in phase with 0.6 mg liraglutide
followed by a 1-week course of 1.2 mg liraglutide,
patients in the active intervention arm will have their first
exercise tolerance test (ETT) at the end of Week 2.
Patients will then be up-titrated to high-dose 1.8 mg
liraglutide for another week before performing a
Week 3 ETT. With a stepwise increase in liraglutide
therapy over a 3-week period we hope to observe a
dose–response effect on exercise haemodynamics. An
initial 1-week run-in phase of once daily 0.6 mg liraglutide
should also allow for improved gastrointestinal tolerability.
Whilst in the placebo arm, patients will have matched-
volume saline injections for the first two weeks before the
Week 2 ETT and then another week of saline injections
before the Week 3 ETT. Patients will then crossover at this
stage so that those in the treatment arm cross to the
placebo arm and vice versa (please refer to Figure 1).
Criteria for terminating an exercise stress test will be:
1) physical exhaustion, 2) severe chest pain, 3) attaining
maximal age-related heart rate, 4) ST-segment depres-
sion (STD) >0.4 mV, or 5) haemodynamically-significant
dysrhythmia.
Sample selection
Potential trial participants fulfilling the inclusion criteria
(Table 4) and who consent will be recruited consecutively
from the following groups:
Table 2 Primary outcome measures
• Change in rate pressure product at 0.1 mV ST-segment depression
during sequential exercise tolerance testing performed over a 6-week
study period
• Change in degree of ST-segment depression at peak exercise during
sequential exercise tolerance testing performed over a 6-week study
period
Table 3 Secondary outcome measures
• Change in total exercise time during sequential exercise tolerance testing performed over a 6-week study period
• Change in time to 0.1 mV ST-segment depression during sequential exercise tolerance testing performed over a 6-week study period
• Change in time to maximum ST-segment depression during sequential exercise tolerance testing performed over a 6-week study period
• Change in recovery time to 0.05 mV ST-segment depression during sequential exercise tolerance testing performed over a 6-week study period
• Evidence of hypoglycaemia through twice-daily home blood glucose monitoring and once-weekly random serum glucose measurements
• Evidence of renal dysfunction through once-weekly monitoring of serum creatinine, electrolytes and estimated glomerular filtration rate
• Evidence of acute pancreatitis through once weekly monitoring of serum amylase alongside telephone and once-weekly face-to-face study visits
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 Patients with known obstructive CAD on
angiography and a previously abnormal exercise test,
but who are currently stable on conservative
medical management, will be enrolled from general
cardiology outpatient clinic.
 Patients with known obstructive CAD on
angiography and evidence of reversible myocardial
ischaemia on exercise testing, awaiting elective
percutaneous coronary intervention (PCI) or
coronary artery bypass graft (CABG) surgery.
Sample size calculation
The host department has shown that the time taken to
0.1 mV STD (368 ± 34→ 418 ± 36 seconds) and the rate
pressure product at 0.1 mV STD (20500 ± 755→ 21907 ±
764 mmHg/min) is significantly increased during the
second of two serial exercise tests separated by 15 minutes
in chronic CAD patients with known left anterior
descending artery stenoses [47,48]. This effect is attributed
to warm-up angina, which is thought to augment the
innate resistance of the myocardium to an ischaemic
insult [51,52]. We would expect the administration of
Liraglutide to mimic the beneficial cardioprotective effects
of warm-up angina. A sample size of 26 patients rando-
mised in a 1:1 fashion to each treatment arm (taking into
consideration a >10% drop-out rate) followed by crossover
would have 90% power to detect a difference between
the means of approximately 15% (2-sided α = 0.05).
Randomisation procedure
All randomisations will be performed through a computer-
generated randomisation program (www.sealedenvelope.
com) in a 1:1 randomisation ratio utilising a study-
specific ID assigned to each enrolled patient. Treatment
allocation can be unblinded in case of an emergency
or serious adverse event if deemed necessary by the
investigator.
Study agent and placebo comparator
Liraglutide will be supplied to trial recruits in pre-filled
single-use plastic syringes ready for once daily subcutane-
ous injection at doses of 0.6 mg, 1.2 mg and 1.8 mg.
Matched-volume saline placebo will also be supplied in
identical pre-filled syringes for subcutaneous injection.
Study medication will be produced and dispensed by
the Aseptic Services Unit of St Thomas’ Hospital
Pharmacy as a set of 7 separate disposable syringes at
the beginning of each study week. Patients will be
asked to store these in a refrigerator and to dispose
of their used syringes in a sharps bin. The sealed bin
will be brought to the next study visit to check for
compliance with the study agents. Patients will be ad-
vised to administer their study agent at approximately
the same time each day to reinforce compliance. The
recommended injection site will be the abdomen, and
that injection site around the abdomen should be varied
from day to day.
Table 4 Inclusion criteria
• Men and women aged 18-80
• Patients must be able to walk confidently on an exercise treadmill
• Patient must have a recent abnormal exercise tolerance test demonstrating >0.1 mV of planar or down-sloping ST-segment depression
• Patients must have angiographic evidence of a >70% stenosis in a main epicardial coronary artery, with or without coronary stenoses elsewhere
• Patients must have a normal resting electrocardiogram in sinus rhythm without bundle branch aberration or other conduction disturbance
• Patients must have preserved left ventricular systolic function (ejection fraction ≥40%)
Table 5 Exclusion criteria
• An abnormal resting electrocardiogram including atrial fibrillation, bundle brunch aberration or other conduction disturbance
• Pre-existing significant left ventricular systolic dysfunction (ejection fraction <40%)
• Pre-existing ischaemic or non-ischaemic cardiomyopathy
• Pre-existing haemodynamically significant valvular heart disease
• Inability to safely negotiate an exercise treadmill
• Patients with Type 1 diabetes mellitus
• Patients with Type 2 diabetes mellitus taking oral and/or subcutaneous anti-diabetic therapy
• Patients with a personal or family history of medullary thyroid carcinoma
• Patients with Multiple Endocrine Neoplasia syndrome type 2
• Patients with acute renal failure or deteriorating renal function
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Concomitant medication
Study participants will have any heart rate-limiting
drugs cautiously withdrawn prior to commencing the
6-week trial protocol. These include beta-blockers,
rate-limiting calcium antagonists (e.g., diltiazem and
verapamil), and ivabradine to ensure a normal chron-
otropic response to exercise stress testing. Long-
acting oral nitrates and nicorandil will also be
stopped to avoid any potential interference with
haemodynamic physiology. Patients will be allowed to
continue their antiplatelet therapy (e.g., aspirin,
clopidogrel, prasugrel, and/or ticagrelor), ACE-
inhibitors, angiotensin receptor blockers, and statins.
Patients will also continue their sublingual glyceryl tri-
nitrate (GTN) spray or buccal GTN to relieve break-
through angina. Those patients experiencing poor
control of pre-existing hypertension following the ces-
sation of the drugs listed previously will be prescribed
alternative antihypertensive medication at the discre-
tion of the investigator, or have their current medica-
tion they can continue up-titrated, and monitored
closely for response.
Figure 1 The LIONESS Trial study design.
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Study visits and procedures
Screening Visit
Once a patient is deemed to have adequately fulfilled the
inclusion and exclusion criteria, informed consent will be
obtained. Part of the inclusion criteria includes the demon-
stration of reversible ischaemia during an ETT. If a recent
ETT is not available, the patient will be asked to perform
an ETT (free of any heart rate-limiting medication for the
past 48 hours) at the screening visit. The result of this ETT
will not be used in the final data analysis but will be cap-
tured as part of the screening process. Those patients ineli-
gible for trial participation will be registered, and the reason
for screening failure will be recorded. Patients entering the
trial will receive a tutorial on home blood glucose monitor-
ing and the signs and symptoms of hypoglycaemia. A safety
information card will be issued. A full medical history and
clinical examination will be performed. Blood tests will be
taken (Table 6). Medications that need to be withheld will
be identified at this visit and withdrawn cautiously (see
Table 7). Those patients successfully recruited will be ran-
domised at this stage.
Trial visits (week 0 to week 6)
Trial participants will perform their first self-administration
of study agent and first blood glucose measurement, which
will be recorded in their patient diary, at trial commence-
ment (Week 0). Both will be supervised by an investigator.
Recruited patients will attend a total of 7 study visits and
have procedures performed according to the schedule
detailed in Table 7. Patients will be asked to record twice
daily home blood glucose measurements at approximately
the same time am and pm. Patients will have blood tests
performed at every study visit (Table 6).
Expected duration of the study
From the point of administration of study drug on day 1
the total length of the study will be 6 weeks. There will
be no follow-up of patients after completion of the 6-week
trial protocol, at which point study drugs will be termi-
nated and patients will have their pre-study medication
recommenced immediately thereafter.
Procedures for recording and reporting adverse events
All study participants will be issued a patient diary in
which they can record any adverse events, side effects,
injection site reactions and angina burden. This diary
will be inspected at every study visit. Patients will also
be able to contact the Main Patient Liaison at all times
for general enquiries and advice regarding any signs and
symptoms they are experiencing pertaining to the study.
The primary care physicians of all study participants will
be issued with an information sheet regarding the potential
side effects of the GLP-1R agonist Liraglutide and the
medication that a patient may have had discontinued prior
to commencing the trial. The importance of informing the
Main Patient Liaison if any adverse events were to occur
will be stressed.
Withdrawal of subjects
Participants will have the right to withdraw from the
study at any time for any reason. Should a patient decide
to withdraw from the study, all efforts will be made to
report the reason for withdrawal as thoroughly as
possible. The investigator also has the right to withdraw
patients from the study in the event of inter-current
illness, adverse events or serious adverse events, protocol
violations, administrative reasons or other reasons.
The study drug will be discontinued and the participant
withdrawn from the study if:
 the participant misses 2 consecutive courses of
treatment;
 the participant decides they no longer wish to
continue;
 if the participant experiences an intolerable degree
of angina as a result of withdrawing their pre-study
heart rate-limiting or anti-anginal medications;
 if the participant experiences significant side effects
from their study medication, in particular excessive or
intolerable nausea, vomiting or diarrhoea; or
 the investigator recommends it.
The Sponsor or Chief Investigator may prematurely
discontinue the study on the basis of new safety in-
formation or for other reasons given by the Study
Steering Committee or Research Ethics Committee
concerned.
Data management and analysis
Data will be collected prospectively using a customised
paper Case Report Form (CRF). Investigators will record
adverse events, injection site reactions, angina episodes
Table 6 Laboratory tests
The following blood tests will be taken at each study visit (Table
7) unless otherwise stated:
• Full blood count
• Creatinine and electrolytes
• Estimated glomerular filtration rate
• Liver function tests
• Amylase
• Corrected calcium
• Random blood glucose
• HBA1c (Week 3 and Week 6 only)
• Random lipid profile (serum total cholesterol, low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol, and triglyceride)
(Week 3 and Week 6 only)
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Table 7 LIONESS trial flowchart of visits and procedures
Screening visit Commence
trial (Week 0)
Study visit
(Week 1)
Exercise test 1
(Week 2)
Exercise test 2
(Week 3)
Study visit
(Week 4)
Exercise test 3
(Week 5)
Exercise test 4
(Week 6)
Obtain informed consent, issue safety
information card and patient diary
Yes - - - - - - -
Randomisation to study agents Yes Perform first
self-administration
of study agent
- - - - - -
Issue 7-day course of blinded study
agent
- Yes Yes Yes Yes Yes Yes Stop all study medication
Check study drug compliance - - Yes Yes Yes Yes Yes Yes
Withdraw protocol-mandated
pre-existing patient medication
Tutorial and
commence
withdrawal
Complete withdrawal - - - - - Recommence pre-existing
patient medication
Home Blood Glucose Monitoring Tutorial and issue
equipment
- Record data
from patient
diary
Record data
from patient
diary
Record data
from patient
diary
Record data
from patient
diary
Record data from
patient diary
Record data from patient
diary
Physical examination Yes Yes Yes Yes Yes Yes Yes Yes
Height measurement Yes - - - - - - -
Weight measurement Yes Yes Yes Yes Yes Yes Yes Yes
Blood pressure measurement Yes Yes Yes Yes Yes Yes Yes Yes
Electrocardiogram Yes - - - - - - -
Pre-specified blood tests Yes Yes Yes Yes Yes Yes Yes Yes
Perform supervised exercise
tolerance test (ETT)
Yes (if recent ETT
unavailable)
- - Yes Yes - Yes Yes
M
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and clinical and laboratory parameters on the CRF at
each study visit.
The fundamental principle underpinning the design of
this trial is that the 2-week period between the Week 3
ETT and the Week 5 ETT (see Figure 1), in those patients
randomised to the active liraglutide intervention first,
should be sufficient to allow adequate washout of the drug
and therefore minimise the impact of a potential carryover
effect. Given that the half-life of liraglutide is 10–14 hours,
this 2-week washout period far exceeds the generally ac-
cepted mark of ≥5 half-lives. A washout period for those
randomised to the placebo arm first would not apply per
se. A preliminary test, such as the Wilcoxon rank sum
test, will be applied to ensure there is no carryover effect.
Once this has been established, standard two-sample
t-tests for independent samples using the intra-individual
differences between the outcomes in both study periods as
the raw data will be utilised [53].
A multiple regression model will be used to compare
treatment, visit number, and patient, using least squares.
Linear regression will be used to study the correlation
between outcome parameters and baseline patient
characteristics. A p value <0.05 will be considered statisti-
cally significant.
Discussion
The study will be conducted in compliance with the
principles of the Declaration of Helsinki (2008), the
principles of Good Clinical Practice and in accord-
ance with all applicable requirements laid down by
the Co-Sponsors of the study, namely: King’s College
London and Guy’s and St Thomas’ NHS Foundation
Trust. The trial protocol has received ethical approval
from the National Research Ethics Service (NRES)
Committee London – Westminster (Research Ethics
Committee reference 11/LO/1564) of the United Kingdom.
Annual progress and safety reports and a final report
at conclusion of the study will be submitted to the
Co-Sponsors and the Research Ethics Committee. The
Medicines and Healthcare Products Regulatory Agency
(MHRA) has also approved the study.
This trial has been funded by the British Heart
Foundation via a Clinical Research Training Fellowship
awarded to Dr Aung Myat (grant number FS/11/70/
28917) and is supported by the Department of Health via
the National Institute of Health Research comprehensive
Biomedical Research Centre award to Guy’s and St
Thomas’ NHS Foundation Trust in partnership with
King’s College London and King’s College Hospital NHS
Foundation Trust.
The LIONESS study is a single-centre trial based in
the United Kingdom. The trial has, therefore, been regis-
tered with our national trials database via the National
Institute of Health Research Clinical Research Network
(NIHR CRN) portfolio (Study ID 11112) since May 4th
2012. The NIHR CRN trials database is accessible to the
public at no charge, open to all prospective registrants,
managed by a not-for-profit organization, has a mechan-
ism to ensure the validity of the registration data, and is
electronically searchable. The study has also been regis-
tered on ClinicalTrials.gov as of November 10th 2014
(NCT02315001). There have been minor amendments to
the study protocol since first registration and as such the
first patient was recruited in January 2014. The study
remains actively recruiting as of February 2015.
It is intended that positive or negative study results
will be reported and disseminated at international con-
ferences and in an international peer-reviewed scientific
journal.
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